KindredBio’s monoclonal antibody a promising parvovirus treatment
by Katie Pfaff
The pet-focused pharmaceutical company, Kindred Biosciences, Inc., shared results from its pivotal efficacy study of the monoclonal antibody, KIND-030, for treatment of dogs infected with parvovirus. Results were positive for dogs treated with the investigational drug without any supportive care.
Results for the study’s primary endpoint of survival were 100% in the treatment group compared to 43% survival in placebo. The blinded and randomized study involved dogs that were found to be positive for canine parvovirus and were treated with either placebo or KIND-030 and no other therapies. The mortality rate was 0% in the treatment group versus 57% in the placebo group.
Parvovirus is most common in puppies and has a high fatality rate if not treated, however, no approved treatments are available aside from supportive care which can be costly.
KIND-030, which acts by attaching to the virus thereby blocking the virus from attacking cells, was established in partnership with Elanco Animal Health. Data from a previous study on parvovirus prophylactic treatment was approved by USDA Center for Veterinary Biologics. The current data is planned for submission in June, with potential approval by end of the year.
Source:
Comments
Related Articles
More news
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment